Anjali Arora names this contestant in Top 2 for Bigg Boss 17; it's not Munawar Faruqui, Ankita Lokhande, Anurag Dobhal
Meet woman who worked for 22 years in US, moved to India to build her own firm, funded over 100 startups
Uttar Pradesh to get India's first 'AI city', details inside
Bose invests $10 million in Noise, takes Indian brand’s valuation past $400 million
UGC NET 2023 December answer key to be released soon at ugcnet.nta.ac.in, details here
India
Studies suggest that IGF-1 DES peptide may induce hypertrophy and hyperplasia in various cell types.
DNA Web Team
Updated: Nov 20, 2023, 06:52 PM IST
Insulin-like growth factor-1 DES (a splicing variation) seems to be a shortened and endogenous protein. Studies suggest that IGF-1 DES peptide may induce hypertrophy and hyperplasia in various cell types. Extensive research suggests it may be more effective than regular IGF-1 potentially from an increased bioavailability.
IGF-1 DES inflammation and neurological diseases are now the focus of active research. One important theory under exploration is that IGF-1 DES may possibly support healthy synapses in the brain and neurological system. In addition, it may possibly stimulate the regeneration of muscle and connective tissues, like all forms of IGF-1, which may aid in repairing and preserving these tissues.
IGF-1 DES Peptide: What is it?
The investigations indicate that the N-terminal tripeptide Gly-Pro-Glu is absent in IGF-1 DES, making it a shortened protein version. The cellular effects of IGF-1 DES seem to be more powerful than those of IGF-1, potentially as it is not considered to be bound to IGF-1 binding proteins. Because of this, it is hypothesized that IGF-1 DES may be around ten times more effective than IGF-1 in stimulating muscle growth and cell division.
Recently, IGF-1 DES has been under investigation within the context of several neurological and neurodevelopmental problems. [i] Research has suggested that IGF-1 and its analogs may affect neuronal synapse health. The IGF-1 DES and the IGF-1 may exhibit some capacity to alleviate symptoms and enhance many behavioral features of autism, speculated strictly through animal models.
IGF-1 DES Peptide: Mechanism of Action
IGF-1 hormone peptides are categorized as insulin-binding proteins because of their potential to interact with IGF-1 receptors. Recent studies [ii] have offered insight into the potential channels by which IGF-1 DES may exert its effects.
IGF-1 DES Peptide and Neuroprotection
The IGF-1 DES peptide appears to significantly impact the development of new synapses, suggesting it may be involved in fundamental cognitive processes like learning and memory. Studies suggest that IGF-1 is important in establishing and maintaining functional synapses. Recent studies suggest that IGF-1 is essential for maintaining adequate amounts of the presynaptic protein synapsin-1, which controls neurotransmitter release. Additionally, IGF-1 seems to be involved in the post-synaptic protein PSD-95, which is thought to be in charge of preserving synaptic structure.
Rett syndrome and chromosome 22 deletion syndrome are two disorders that have been documented to respond well to IGF-1 and its analogs. Researchers speculate that it "has suggested reversing the decrease in the number of excitatory synapses and the density of neurons that characterize these illnesses in animal studies"; therefore, it is being presented as an experimental compound in further studies.
Research on the potential impact of IGF-1 on neurological disorders such as MS, ALS, PD, and AD has been found to have conflicting results. IGF-1 research in ALS suggested promising signs of slowing the disease's course, boosting muscular strength, and improving respiratory function. However, it seems that IGF-1 had little effect on MS, potentially because the disease affects the cells surrounding neurons rather than directly killing them. Although other studies of IGF-1 for PD have not yet been published, speculative data in animal models have suggested promise in preserving dopaminergic neurons and enhancing behavior.
IGF-1 DES Peptide and Autism
The possible role of IGF-1 in various neurological disorders, including autism, has been posited by limited scientific research. Brain-derived IGF-1 levels seem to be lower in younger autistic models compared to age-matched controls. Since "the action of IGF-1 is (reportedly) most pronounced in the developing brain," this finding implies that reduced concentrations of IGF-1 in the brain, especially during early developmental stages, may disturb normal neurodevelopment and contribute to the pathophysiology of autism.
A five-day study of IGF-1 DES in a mouse model suggested potential impacts as a result of the peptide in terms of the rodents' social behavior, recognition of novel objects, contextual fear conditioning, reduction of repetitive/compulsive behavior, grooming, and memory. [vi] Autism is thought to originate from disruptions in synapse formation. Autism is a neurodevelopmental disorder that bears pathological characteristics with other disorders such as fragile X syndrome, tuberous sclerosis, and Angelman syndrome.
IGF-1 DES Peptide and the Brain
Research suggests analogs like IGF-1 DES may be more potent than the original IGF-1 molecule as IGF-1 appears to undergo extensive changes in the brain, perhaps generating shorter versions. It seems that the capacity of these modified molecules, especially IGF-1 DES, to traverse the blood-brain barrier has been improved. Researchers have hypothesized that IGF-1 and its analogs may have the capacity to reduce neuronal death and offer neuroprotection against neurodegenerative diseases. [vii]
Research on rats has suggested that IGF-1 DES may also improve synaptic transmission and benefit cognition. As endogenous IGF-1 levels naturally decrease over time, this may elucidate future research in learning and memory functions. Studies suggest that excitatory post-synaptic potentials may be significantly boosted by 40% when IGF-1 DES is presented. [viii]
Purchasing research peptides for study is permissible but human consumption and personal use is strictly prohibited by law.
References
[i] Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des (1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996 Oct;28(10):1085-7. doi: 10.1016/1357-2725(96)00056-8. PMID: 8930132. https://pubmed.ncbi.nlm.nih.gov/8930132/
[ii] Melinda M. Ramsey et al, Functional Characterization of Des-IGF-1 Action at Excitatory Synapses in the CA1 Region of Rat Hippocampus, 01 Jul 2005. https://journals.physiology.org/doi/full/10.1152/jn.00768.2004
[iii] Canitano R. New experimental treatments for core social domain in autism spectrum disorders. Front Pediatr. 2014 Jun 20;2:61. doi: 10.3389/fped.2014.00061. PMID: 24999471; PMCID: PMC4064155. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064155/
[iv] Costales J, Kolevzon A. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev. 2016 Apr;63:207-22. doi: 10.1016/j.neubiorev.2016.01.001. Epub 2016 Jan 15. PMID: 26780584; PMCID: PMC4790729. https://pubmed.ncbi.nlm.nih.gov/26780584/
[v] Riikonen R. Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children. Int J Mol Sci. 2017 Sep 26;18(10):2056. doi: 10.3390/ijms18102056. PMID: 28954393; PMCID: PMC5666738. https://pubmed.ncbi.nlm.nih.gov/28954393/
[vi] Adam B. Steinmetz et al., Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice, Journal of Neuroscience 24 January 2018, 38 (4) 1015-1029; DOI: https://doi.org/10.1523/JNEUROSCI.2010-17.2017
[vii] Ebrahimi-Fakhari D, Sahin M. Autism and the synapse: emerging mechanisms and mechanism-based therapies. Curr Opin Neurol. 2015 Apr;28(2):91-102. https://pubmed.ncbi.nlm.nih.gov/25695134/
[viii] Górecki DC, Beresewicz M, Zabłocka B. Neuroprotective effects of short peptides derived from the Insulin-like growth factor 1. Neurochem Int. 2007 Dec;51(8):451-8. doi: 10.1016/j.neuint.2007.04.030. Epub 2007 May 16. PMID: 17582656. https://pubmed.ncbi.nlm.nih.gov/17582656/
Disclaimer: Above mentioned article is a consumer connect initiative. This article is a paid publication and does not have journalistic/editorial involvement of IDPL, and IDPL claims no responsibility whatsoever.
Israel Hamas war: Second aid convoy reaches Gaza as Israel occupied West bank
Operation Ajay: Sixth flight carrying 143 people, including two Nepalese reaches India from Israel
Israel strikes Gaza, Lebanon overnight, prime minister Benjamin Netanyahu conducts top level meeting
Israel Hamas war day 17: At least 70 killed in overnight Israel strikes on Gaza
Israel-Hamas war: Who are the Bedouin Arabs supporting Israel against Hamas?
About The Author
More Stories
From Curiosity to Confidence: CodificaKids Builds Digital Trust in Rural Brazil
Community Snapshot—August
Empowering Parents in Rwanda Through Digital Literacy Training